01 — At a Glance
The Ambitious CDMO That’s Running on Fumes & Spreadsheet Projections
- 52-Week High / Low₹322 / ₹154
- Q3 FY26 Revenue₹720 Cr
- Q3 FY26 PAT₹-13 Cr
- EPS (TTM)₹7.58
- 3-Month Return-38.2%
- Book Value / Share₹406
- Price to Book0.39x
- ROE (TTM)-0.32%
- Net Debt / EBITDA3.92x
- Credit RatingIND A/Negative
Flash Summary: DCAL reported Q3 PAT of ₹-13 crore — yes, they lost money last quarter. Revenue of ₹720 crore is growing at 5.5% YoY, which sounds fine until you realise EBITDA margins collapsed from 22.8% to 15.7%, and Ind-Ra just downgraded their NCDs from A+ Stable to A/Negative on February 18, 2026. The stock has crashed 48.5% in six months. Management is still going on earnings calls talking about ₹500 crore India revenue targets and ADC powerhouses. Someone should tell them the French facility is running at 20% capacity and bleeding cash. But first, let’s understand how a company with a ₹22 lakh crore addressable market in global pharma CDMO can’t seem to actually make money.
02 — Introduction
The CDMO That Promised The Moon. And Built Half a Spaceship.
Dishman Carbogen Amcis Limited (DCAL) is a Contract Research and Manufacturing Services (CRAMS) provider. Translation: you’re a big pharma company trying to develop a drug, you give DCAL a briefcase full of molecules, and they turn it into a commercial pill. It’s a high-touch, high-margin business — theoretically. DCAL operates 25 manufacturing plants across India, Switzerland, France, the UK, Netherlands, and China, all blessed by the FDA, PMDA, EDQM, and a alphabet soup of other regulatory bodies.
Here’s the plot twist: in 2017, the European regulators found some GMP compliance issues at their Bavla facility in Gujarat. The audits were so brutal that DCAL spent the next five years in the regulatory dungeon, unable to take on new customers, unable to ramp capacity, unable to do anything except fix the damn facility. Hundreds of millions were spent. Certifications were painstakingly rebuilt. It was supposed to be a comeback story.
Fast forward to Q3 FY26: they finally got their US FDA approval in May 2024, EDQM cleared them in February 2024, and PMDA blessed them in August 2023. All clear. The comeback is on. Except the moment they got access back to the market, they realised: everyone else had already moved on. Competitors had filled the void. Pricing had compressed. And now DCAL is trying to wrestle back market share while simultaneously running a brand-new facility in France that was supposed to be a margin powerhouse but is instead a margin crematorium.
The Concall Said (Feb 2026): “More RFPs, more projects secured… increased interest in late-phase projects.” Translation: we’re winning some deals now, but the deals we’re winning are cheap. The really profitable work (blockbuster late-phase manufacturing) is dominated by the players who never lost access — Catalent, Lonza, Samsung BioLogics. DCAL is competing on cost and capability, not on relationships.
03 — Business Model: The Casio of Global CDMOs
You Make Good Watches. But Sony Already Has The Cool Factor.
DCAL operates a two-legged business: CRAMS (88% of revenue) and Marketable Molecules (12%). Let’s break it down with the amount of honesty a management team fears.
CRAMS is the main engine. Within CRAMS, there are two subs: Carbogen Amcis (91% of CRAMS, primarily in Europe) handles process R&D, drug substance manufacturing, and recently added drug product (injectables). Dishman India (9% of CRAMS) does similar work but from Indian facilities. The idea: offer end-to-end services from early-phase development all the way to commercial manufacturing.
Marketable Molecules is the forgettable sidekick. Specialty chemicals, Vitamin D3 analogues, generic APIs — all the stuff that doesn’t make headline news but keeps operations running.
Here’s the problem: CRAMS is brutally capital intensive and relationship-driven. You need world-class facilities (check), FDA approvals (now check), and customer relationships developed over years (not quite check, because EDQM happened). The margins look great on paper — pre-EDQM EBITDA was 28%. But post-reopening? They’re at 19.7%, and that’s with “a huge amount of revenue coming from development” (management’s words, meaning cheap work).
CRAMS Revenue Mix84%of 9M FY26
Carbogen Amcis91%of CRAMS
France Site Capacity20%utilization
On-Time Projects???ask CEO
Management’s Grand Vision (from Feb concall): “We want to be the only end-to-end ADC platform — antibody to conjugation to drug product.” Meaning: not just make the active ingredient, but also make the fancy injectable bottle, all under one roof. It sounds powerful. But the reality is: Carbogen Amcis had to co-invest CHF 25 million with a Japanese customer just to expand capacity for that customer’s ADCs. That’s not supplier-customer, that’s joint venture desperation.
04 — Financials Overview: When The Numbers Write Their Own Tragedy
Q3 FY26: Margin Collapse Edition
Result Type: Quarterly Results | Q3 EPS: ₹-0.83 | 9M EPS (April-Dec 2025): Frankly Messy
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 720 | 682 | 653 | +5.5% | +10.3% |
| EBITDA | 113 | 155 | 149 | -27.1% | -24.2% |
| EBITDA Margin % | 15.7% | 22.8% | 22.8% | -710 bps | -710 bps |
| PAT | -13 | 5 | 65 | LOSS | -120% |
| EPS (₹) | -0.83 | 0.30 | 4.16 | LOSS | -120% |
What Actually Happened Here: Revenue barely grew 5.5% YoY, but EBITDA margins tanked 710 basis points — from 22.8% to 15.7%. Why? Three things. First, product mix shifted: more “development revenue” (cheap work) and less “commercial revenue” (profitable work). Second, the French facility — which was supposed to print money — is instead printing losses. The concall disclosed it was only at 20% utilization in Q3. Third, there was a ₹20 crore shipment delay into January due to “intermediate supply delay and European holidays,” which in Q3 looks like a revenue miss. And let’s not forget: finance cost of ₹45.7 crore included one-time items for syndicated facility refinancing.
💬 Here’s the awkward truth: if Q3 revenue was supposed to be ₹740 crore (accounting for the delayed shipment), but they’re losing money anyway, is this actually a revenue timing issue or a margin compression problem? What’s your bet — execution or business model?
05 — Valuation: The Discount Is Earned, Not A Gift
Trading At 0.39x Book Value. There’s Probably A Reason.
